CoChat
Sign Up
Cited by 1,074Mesenchymal stem cell researchPluripotent Stem Cells ResearchHematopoietic Stem Cell Transplantation

Stem cell-based therapy for human diseases

Open access
Hoang, Duc M., Pham, Phuong T., Bach, Trung Q., Ngo, Anh T. L., Nguyen, Quyen T., Phan, Trang T. K., Nguyen, Giang H., Le, Phuong T. T. +4 more·2022·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-022-01134-4PMC PMC9357075
Open this paper in CoChat — free accountOpen PDF

Abstract

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-01134-4

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • UC/WJ-MSCs have potent immunomodulatory properties, rapid proliferation, and off-the-shelf availability, enabling faster improvements in decompensated cirrhosis and acute liver failure.

    “Their potent immunomodulatory properties, rapid proliferation, and ‘off-the-shelf’ availability enable faster improvements in decompensated cirrhosis and acute liver failure [79].”

    From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [79]

    The overview of MSC tissue origins describes UC-MSCs’ rapid proliferation and immunoregulatory functions, while the pulmonary-disease mechanism section calls them “off-the-shelf” products. The Liver diseases section reports improved liver function in patients with decompensated cirrhosis and short-term outcomes for stem-cell therapy in acute-on-chronic liver failure. It does not establish that those UC/WJ-MSC properties enable faster improvement in either condition, or report that result for acute liver failure specifically. Page numbers were not supplied in our copy. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

  • UC/WJ-MSCs emerge as a potentially highly effective source, particularly for allogeneic use.

    “UC/WJ-MSCs emerge as a potentially highly effective source, particularly for allogeneic use.”

    From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [79]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 481

  1. [1]Mellman I Coukos G Dranoff G Cancer immunotherapy comes of age Nature 2011 480 480 489 10.1038/nature10673 22193102 PMC3967235 · DOI · Paper page
  2. [2]Ancans J Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development Front. Immunol. 2012 3 253 10.3389/fimmu.2012.00253 22912639 PMC3418507 · DOI
  3. [3]Yin JQ Zhu J Ankrum JA Manufacturing of primed mesenchymal stromal cells for therapy Nat. Biomed. Eng. 2019 3 90 104 10.1038/s41551-018-0325-8 30944433 · DOI
  4. [4]O’Brien T Barry FP Stem cell therapy and regenerative medicine Mayo Clin. Proc. 2009 84 859 861 10.4065/84.10.859 19797773 PMC2755803 · DOI
  5. [5]Mousaei Ghasroldasht, M., Seok, J., Park, H. S., Liakath Ali, F. B. & Al-Hendy, A. Stem cell therapy: from idea to clinical practice. Int. J. Mol. Sci. 23, 2850 (2022). PMC8911494 35269990
  6. [6]Kuriyan AE Vision loss after intravitreal injection of autologous “stem cells” for AMD N. Engl. J. Med. 2017 376 1047 1053 10.1056/NEJMoa1609583 28296617 PMC5551890 · DOI
  7. [7]Biehl JK Russell B Introduction to stem cell therapy J. Cardiovasc. Nurs. 2009 24 98 103 10.1097/JCN.0b013e318197a6a5 19242274 PMC4104807 · DOI
  8. [8]Srijaya TC Ramasamy TS Kasim NH Advancing stem cell therapy from bench to bedside: lessons from drug therapies J. Transl. Med. 2014 12 243 10.1186/s12967-014-0243-9 25182194 PMC4163166 · DOI
  9. [9]Ramalho-Santos M Willenbring H On the origin of the term “stem cell” Cell Stem Cell 2007 1 35 38 10.1016/j.stem.2007.05.013 18371332 · DOI
  10. [10]Konstantinov IE In search of Alexander A. Maximow: the man behind the unitarian theory of hematopoiesis Perspect. Biol. Med. 2000 43 269 276 10.1353/pbm.2000.0006 10804590 · DOI
  11. [11]Droscher A Images of cell trees, cell lines, and cell fates: the legacy of Ernst Haeckel and August Weismann in stem cell research Hist. Philos. Life Sci. 2014 36 157 186 10.1007/s40656-014-0028-8 25515356 · DOI
  12. [12]Jansen J The first successful allogeneic bone-marrow transplant: Georges Mathe Transfus. Med. Rev. 2005 19 246 248 10.1016/j.tmrv.2005.02.006 16010655 · DOI
  13. [13]Blume KG Weissman ILE Donnall Thomas (1920-2012) Proc. Natl Acad. Sci. USA 2012 109 20777 20778 10.1073/pnas.1218913109 23197829 PMC3529056 · DOI
  14. [14]Cheng M Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A Clin. Transpl. 2013 27 326 329 10.1111/ctr.12072 23331048 · DOI
  15. [15]Thomas ED Aplastic anaemia treated by marrow transplantation Lancet 1972 1 284 289 10.1016/S0140-6736(72)90292-9 4109931 · DOI
  16. [16]Friedenstein AJ Chailakhyan RK Gerasimov UV Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers Cell Tissue Kinet. 1987 20 263 272 3690622
  17. [17]Friedenstein AJ Chailakhjan RK Lalykina KS The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells Cell Tissue Kinet. 1970 3 393 403 5523063
  18. [18]Caplan AI Mesenchymal stem cells J. Orthop. Res. 1991 9 641 650 10.1002/jor.1100090504 1870029 · DOI
  19. [19]Bolli R Tang XL Guo Y Li Q After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease Can. J. Physiol. Pharm. 2021 99 129 139 10.1139/cjpp-2020-0406 PMC8299902 32937086 · DOI
  20. [20]Liu C Han D Liang P Li Y Cao F The current dilemma and breakthrough of stem cell therapy in ischemic heart disease Front. Cell Dev. Biol. 2021 9 636136 10.3389/fcell.2021.636136 33968924 PMC8100527 · DOI
  21. [21]Zhang J Basic and translational research in cardiac repair and regeneration: JACC state-of-the-art review J. Am. Coll. Cardiol. 2021 78 2092 2105 10.1016/j.jacc.2021.09.019 34794691 PMC9116459 · DOI
  22. [22]Gyongyosi M Wojakowski W Navarese EP Moye LA Investigators A Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies Circ. Res. 2016 118 1254 1263 10.1161/CIRCRESAHA.115.307347 27081108 PMC4834852 · DOI
  23. [23]Okamoto R Matsumoto T Watanabe M Regeneration of the intestinal epithelia: regulation of bone marrow-derived epithelial cell differentiation towards secretory lineage cells Hum. Cell 2006 19 71 75 10.1111/j.1749-0774.2006.00010.x 16879559 · DOI
  24. [24]Gehart H Clevers H Tales from the crypt: new insights into intestinal stem cells Nat. Rev. Gastroenterol. Hepatol. 2019 16 19 34 10.1038/s41575-018-0081-y 30429586 · DOI
  25. [25]Santos AJM Lo YH Mah AT Kuo CJ The intestinal stem cell niche: homeostasis and adaptations Trends Cell Biol. 2018 28 1062 1078 10.1016/j.tcb.2018.08.001 30195922 PMC6338454 · DOI
  26. [26]Roda G Crohn’s disease Nat. Rev. Dis. Prim. 2020 6 22 10.1038/s41572-020-0156-2 32242028 · DOI
  27. [27]Kobayashi T Ulcerative colitis Nat. Rev. Dis. Prim. 2020 6 74 10.1038/s41572-020-0205-x 32913180 · DOI
  28. [28]Gratwohl A Autologous hematopoietic stem cell transplantation for autoimmune diseases Bone Marrow Transpl. 2005 35 869 879 10.1038/sj.bmt.1704892 15765114 · DOI
  29. [29]Kashyap A Forman SJ Autologous bone marrow transplantation for non-Hodgkin’s lymphoma resulting in long-term remission of coincidental Crohn’s disease Br. J. Haematol. 1998 103 651 652 10.1046/j.1365-2141.1998.01059.x 9858212 · DOI
  30. [30]Hurley JM Lee SG Andrews RE Jr. Klowden MJ Bulla LA Jr. Separation of the cytolytic and mosquitocidal proteins of Bacillus thuringiensis subsp. israelensis Biochem Biophys. Res. Commun. 1985 126 961 965 10.1016/0006-291X(85)90279-7 2858208 · DOI
  31. [31]Oyama Y Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease Gastroenterology 2005 128 552 563 10.1053/j.gastro.2004.11.051 15765390 · DOI
  32. [32]Burt RK Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up Blood 2010 116 6123 6132 10.1182/blood-2010-06-292391 20837778 · DOI
  33. [33]Hasselblatt P Remission of refractory Crohn’s disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation Aliment Pharm. Ther. 2012 36 725 735 10.1111/apt.12032 22937722 · DOI
  34. [34]Hawkey CJ Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial J. Am. Med. Assoc. 2015 314 2524 2534 10.1001/jama.2015.16700 26670970 · DOI
  35. [35]Lindsay JO Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial Lancet Gastroenterol. Hepatol. 2017 2 399 406 10.1016/S2468-1253(17)30056-0 28497755 · DOI
  36. [36]Wang R Stem cell therapy for Crohn’s disease: systematic review and meta-analysis of preclinical and clinical studies Stem Cell Res Ther. 2021 12 463 10.1186/s13287-021-02533-0 34407875 PMC8375136 · DOI
  37. [37]Hawkey CJ Hematopoietic stem cell transplantation in Crohn’s disease: state-of-the-art treatment Dig. Dis. 2017 35 107 114 10.1159/000449090 28147358 · DOI
  38. [38]Si-Tayeb K Lemaigre FP Duncan SA Organogenesis and development of the liver Dev. Cell 2010 18 175 189 10.1016/j.devcel.2010.01.011 20159590 · DOI · Paper page
  39. [39]Xue R Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis J. Transl. Med. 2018 16 126 10.1186/s12967-018-1464-0 29747694 PMC5946490 · DOI
  40. [40]Shi M Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients Stem Cells Transl. Med. 2012 1 725 731 10.5966/sctm.2012-0034 23197664 PMC3659658 · DOI
  41. [41]Liu Y Dong Y Wu X Xu X Niu J The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials Stem Cell Res. Ther. 2022 13 204 10.1186/s13287-022-02882-4 35578365 PMC9109309 · DOI
  42. [43]Gordon MY Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor Stem Cells 2006 24 1822 1830 10.1634/stemcells.2005-0629 16556705 · DOI
  43. [44]Arroyo V Acute-on-chronic liver failure in cirrhosis Nat. Rev. Dis. Prim. 2016 2 16041 10.1038/nrdp.2016.41 27277335 · DOI
  44. [45]Zhang Z Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients J. Gastroenterol. Hepatol. 2012 27 Suppl 2 112 120 10.1111/j.1440-1746.2011.07024.x 22320928 · DOI · Paper page
  45. [47]Xu L Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells J. Gastroenterol. Hepatol. 2014 29 1620 1628 10.1111/jgh.12653 24942592 · DOI
  46. [49]Fang X A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis J. Gastroenterol. Hepatol. 2018 33 774 780 10.1111/jgh.14081 29293276 · DOI · Paper page
  47. [50]Mohamadnejad M Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis Liver Int. 2013 33 1490 1496 10.1111/liv.12228 23763455 · DOI · Paper page
  48. [51]Nguyen TL Autologous bone marrow mononuclear cell infusion for liver cirrhosis after the Kasai operation in children with biliary atresia Stem Cell Res. Ther. 2022 13 108 10.1186/s13287-022-02762-x 35287722 PMC8919575 · DOI · Paper page
  49. [52]Bai YQ Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis World J. Gastroenterol. 2014 20 8660 8666 10.3748/wjg.v20.i26.8660 25024623 PMC4093718 · DOI
  50. [53]Guo C Long-term outcomes of autologous peripheral blood stem cell transplantation in patients with cirrhosis Clin. Gastroenterol. Hepatol. 2019 17 1175 1182 e1172 10.1016/j.cgh.2018.10.034 30613001 · DOI
  51. [54]Newsome PN Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial Lancet Gastroenterol. Hepatol. 2018 3 25 36 10.1016/S2468-1253(17)30326-6 29127060 PMC5738975 · DOI · Paper page
  52. [56]Maurice J Manousou P Non-alcoholic fatty liver disease Clin. Med. 2018 18 245 250 10.7861/clinmedicine.18-3-245 PMC6334080 29858436 · DOI
  53. [58]Sakai Y Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy Regen. Ther. 2021 18 97 101 10.1016/j.reth.2021.04.003 34095367 PMC8165289 · DOI
  54. [59]Mieli-Vergani G Autoimmune hepatitis Nat. Rev. Dis. Primers 2018 4 18018 10.1038/nrdp.2018.17 29644995 · DOI
  55. [60]Calore E Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease Bone Marrow Transpl. 2018 53 644 646 10.1038/s41409-017-0065-5 29335630 · DOI
  56. [61]Vento S Cainelli F Renzini C Ghironzi G Concia E Resolution of autoimmune hepatitis after bone-marrow transplantation Lancet 1996 348 544 545 10.1016/S0140-6736(05)64700-9 8757165 · DOI
  57. [62]Terziroli Beretta-Piccoli B Mieli-Vergani G Vergani D Autoimmmune hepatitis Cell Mol. Immunol. 2022 19 158 176 10.1038/s41423-021-00768-8 34580437 PMC8475398 · DOI
  58. [63]Wang L Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis J. Gastroenterol. Hepatol. 2013 28 Suppl 1 85 92 10.1111/jgh.12029 23855301 · DOI · Paper page
  59. [64]Wang L Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis Stem Cells Dev. 2014 23 2482 2489 10.1089/scd.2013.0500 24835895 · DOI · Paper page
  60. [65]Martel-Pelletier J Osteoarthritis Nat. Rev. Dis. Prim. 2016 2 16072 10.1038/nrdp.2016.72 27734845 · DOI
  61. [66]Olsson S Akbarian E Lind A Razavian AS Gordon M Automating classification of osteoarthritis according to Kellgren-Lawrence in the knee using deep learning in an unfiltered adult population BMC Musculoskelet. Disord. 2021 22 844 10.1186/s12891-021-04722-7 34600505 PMC8487469 · DOI
  62. [67]Mahmoudian A Lohmander LS Mobasheri A Englund M Luyten FP Early-stage symptomatic osteoarthritis of the knee—time for action Nat. Rev. Rheumatol. 2021 17 621 632 10.1038/s41584-021-00673-4 34465902 · DOI
  63. [68]Kubsik-Gidlewska A CD34+ stem cell treatment for knee osteoarthritis: a treatment and rehabilitation algorithm J. Rehabil. Med Clin. Commun. 2018 3 1000012 10.2340/20030711-1000012 33884126 PMC8011677 · DOI
  64. [69]Jevotovsky DS Alfonso AR Einhorn TA Chiu ES Osteoarthritis and stem cell therapy in humans: a systematic review Osteoarthr. Cartil. 2018 26 711 729 10.1016/j.joca.2018.02.906 29544858 · DOI
  65. [70]Wiggers TG Winters M Van den Boom NA Haisma HJ Moen MH Autologous stem cell therapy in knee osteoarthritis: a systematic review of randomised controlled trials Br. J. Sports Med 2021 55 1161 1169 10.1136/bjsports-2020-103671 34039582 · DOI
  66. [71]Han SB Seo IW Shin YS Intra-articular injections of hyaluronic acid or steroids associated with better outcomes than platelet-rich plasma, adipose mesenchymal stromal cells, or placebo in knee osteoarthritis: a network meta-analysis Arthroscopy 2021 37 292 306 10.1016/j.arthro.2020.03.041 32305424 · DOI
  67. [72]Bastos R Intra-articular injections of expanded mesenchymal stem cells with and without addition of platelet-rich plasma are safe and effective for knee osteoarthritis Knee Surg. Sports Traumatol. Arthrosc. 2018 26 3342 3350 10.1007/s00167-018-4883-9 29511819 · DOI
  68. [73]Molnar, V. et al. Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. Genes13, 949 (2022). PMC9222975 35741711
  69. [74]Barisic S Childs RW Graft-versus-solid-tumor effect: from hematopoietic stem cell transplantation to adoptive cell therapies Stem Cells 2022 40 556 563 10.1093/stmcls/sxac021 35325242 PMC9216497 · DOI
  70. [75]Mello MM Brennan TA The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer Health Aff. (Millwood) 2001 20 101 117 10.1377/hlthaff.20.5.101 11558695 · DOI
  71. [76]Sissung TM Figg WD Stem cell clinics: risk of proliferation Lancet Oncol. 2020 21 205 206 10.1016/S1470-2045(19)30787-9 32007195 · DOI
  72. [77]Fu, X. et al. Mesenchymal stem cell migration and tissue repair. Cells8, 784 (2019). PMC6721499 31357692
  73. [78]Zachar L Bacenkova D Rosocha J Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment J. Inflamm. Res. 2016 9 231 240 10.2147/JIR.S121994 28008279 PMC5170601 · DOI
  74. [79]de Araujo Farias V Carrillo-Galvez AB Martin F Anderson P TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer Cytokine Growth Factor Rev. 2018 43 25 37 10.1016/j.cytogfr.2018.06.002 29954665 · DOI
  75. [80]Ding W Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch Blood 2010 116 2984 2993 10.1182/blood-2010-02-269894 20606160 PMC2974606 · DOI
  76. [81]Ritter E Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells Ann. Surg. 2008 247 310 314 10.1097/SLA.0b013e31816401d5 18216538 · DOI
  77. [82]Cronwright G Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression Cancer Res. 2005 65 2207 2215 10.1158/0008-5472.CAN-04-1882 15781633 · DOI
  78. [83]Aldinucci, D., Borghese, C. & Casagrande, N. The CCL5/CCR5 axis in cancer progression. Cancers12, 1765 (2020). PMC7407580 32630699
  79. [84]Karnoub AE Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 2007 449 557 563 10.1038/nature06188 17914389 · DOI · Paper page
  80. [85]Kucerova L Matuskova M Hlubinova K Altanerova V Altaner C Tumor cell behaviour modulation by mesenchymal stromal cells Mol. Cancer 2010 9 129 10.1186/1476-4598-9-129 20509882 PMC2890609 · DOI
  81. [86]Schmohl KA Muller AM Nelson PJ Spitzweg C Thyroid hormone effects on mesenchymal stem cell biology in the tumour microenvironment Exp. Clin. Endocrinol. Diabetes 2020 128 462 468 10.1055/a-1022-9874 31648351 · DOI
  82. [87]Mishra PJ Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells Cancer Res. 2008 68 4331 4339 10.1158/0008-5472.CAN-08-0943 18519693 PMC2725025 · DOI · Paper page
  83. [88]Liu J Han G Liu H Qin C Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling PLoS ONE 2013 8 e62844 10.1371/journal.pone.0062844 23646150 PMC3639969 · DOI
  84. [89]Ho IA Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis Stem Cells 2013 31 146 155 10.1002/stem.1247 23034897 · DOI
  85. [90]Sun Z Wang S Zhao RC The roles of mesenchymal stem cells in tumor inflammatory microenvironment J. Hematol. Oncol. 2014 7 14 10.1186/1756-8722-7-14 24502410 PMC3943443 · DOI · Paper page
  86. [91]Rhee KJ Lee JI Eom YW Mesenchymal stem cell-mediated effects of tumor support or suppression Int. J. Mol. Sci. 2015 16 30015 30033 10.3390/ijms161226215 26694366 PMC4691158 · DOI
  87. [92]Liang W Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines Cell Mol. Biol. Lett. 2021 26 3 10.1186/s11658-020-00246-5 33472580 PMC7818947 · DOI
  88. [93]Hmadcha A Martin-Montalvo A Gauthier BR Soria B Capilla-Gonzalez V Therapeutic potential of mesenchymal stem cells for cancer therapy Front. Bioeng. Biotechnol. 2020 8 43 10.3389/fbioe.2020.00043 32117924 PMC7013101 · DOI
  89. [94]Cao GD The oncolytic virus in cancer diagnosis and treatment Front. Oncol. 2020 10 1786 10.3389/fonc.2020.01786 33014876 PMC7509414 · DOI
  90. [95]Melen GJ Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells Cancer Lett. 2016 371 161 170 10.1016/j.canlet.2015.11.036 26655276 · DOI
  91. [96]Garcia-Castro J Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study Cancer Gene Ther. 2010 17 476 483 10.1038/cgt.2010.4 20168350 · DOI
  92. [97]Draganov DD Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers J. Transl. Med. 2019 17 100 10.1186/s12967-019-1829-z 30917829 PMC6437877 · DOI
  93. [98]Cyranoski D How human embryonic stem cells sparked a revolution Nature 2018 555 428 430 10.1038/d41586-018-03268-4 29565377 · DOI
  94. [99]Thomson JA Embryonic stem cell lines derived from human blastocysts Science 1998 282 1145 1147 10.1126/science.282.5391.1145 9804556 · DOI
  95. [101]Takahashi K Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 2007 131 861 872 10.1016/j.cell.2007.11.019 18035408 · DOI · Paper page
  96. [102]Gepstein L Derivation and potential applications of human embryonic stem cells Circ. Res. 2002 91 866 876 10.1161/01.RES.0000041435.95082.84 12433831 · DOI
  97. [103]Andrews PW From teratocarcinomas to embryonic stem cells Philos. Trans. R. Soc. Lond. B Biol. Sci. 2002 357 405 417 10.1098/rstb.2002.1058 12028783 PMC1692959 · DOI
  98. [104]Finch BW Ephrussi B Retention of multiple developmental potentialities by cells of a mouse testicular teratocarcinoma during prolonged culture in vitro and their extinction upon hybridization with cells of permanent lines Proc. Natl Acad. Sci. USA 1967 57 615 621 10.1073/pnas.57.3.615 16591508 PMC335553 · DOI
  99. [105]Ried T The consequences of chromosomal aneuploidy on the transcriptome of cancer cells Biochim Biophys. Acta 2012 1819 784 793 10.1016/j.bbagrm.2012.02.020 22426433 PMC4737485 · DOI
  100. [106]Evans MJ Kaufman MH Establishment in culture of pluripotential cells from mouse embryos Nature 1981 292 154 156 10.1038/292154a0 7242681 · DOI
  101. [107]Martin GR Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells Proc. Natl Acad. Sci. USA 1981 78 7634 7638 10.1073/pnas.78.12.7634 6950406 PMC349323 · DOI
  102. [108]Lo B Parham L Ethical issues in stem cell research Endocr. Rev. 2009 30 204 213 10.1210/er.2008-0031 19366754 PMC2726839 · DOI
  103. [109]Wilmut I Schnieke AE McWhir J Kind AJ Campbell KH Viable offspring derived from fetal and adult mammalian cells Nature 1997 385 810 813 10.1038/385810a0 9039911 · DOI
  104. [110]Schwartz SD Embryonic stem cell trials for macular degeneration: a preliminary report Lancet 2012 379 713 720 10.1016/S0140-6736(12)60028-2 22281388 · DOI · Paper page
  105. [111]Atala A Human embryonic stem cells: early hints on safety and efficacy Lancet 2012 379 689 690 10.1016/S0140-6736(12)60118-4 22281387 · DOI
  106. [112]Schwartz SD Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies Lancet 2015 385 509 516 10.1016/S0140-6736(14)61376-3 25458728 · DOI · Paper page
  107. [114]Liu Y Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration Cell Discov. 2018 4 50 10.1038/s41421-018-0053-y 30245845 PMC6143607 · DOI
  108. [115]Limnios IJ Chau YQ Skabo SJ Surrao DC O’Neill HC Efficient differentiation of human embryonic stem cells to retinal pigment epithelium under defined conditions Stem Cell Res. Ther. 2021 12 248 10.1186/s13287-021-02316-7 33883023 PMC8058973 · DOI
  109. [116]Foltz, L. P. & Clegg, D. O. Rapid, directed differentiation of retinal pigment epithelial cells from human embryonic or induced pluripotent stem cells. J. Vis. Exp.128, e56274 (2017). PMC5755280 29155780
  110. [117]Kuroda T Ando S Takeno Y Kishino A Kimura T Robust induction of retinal pigment epithelium cells from human induced pluripotent stem cells by inhibiting FGF/MAPK signaling Stem Cell Res 2019 39 101514 10.1016/j.scr.2019.101514 31376722 · DOI
  111. [118]Dewell TE Transcription factor overexpression drives reliable differentiation of retinal pigment epithelium from human induced pluripotent stem cells Stem Cell Res. 2021 53 102368 10.1016/j.scr.2021.102368 34087997 · DOI
  112. [119]Dehghan S Mirshahi R Shoae-Hassani A Naseripour M Human-induced pluripotent stem cells-derived retinal pigmented epithelium, a new horizon for cells-based therapies for age-related macular degeneration Stem Cell Res. Ther. 2022 13 217 10.1186/s13287-022-02894-0 35619143 PMC9137077 · DOI
  113. [120]Menasche P Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report Eur. Heart J. 2015 36 2011 2017 10.1093/eurheartj/ehv189 25990469 · DOI · Paper page
  114. [121]Menasche P Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction J. Am. Coll. Cardiol. 2018 71 429 438 10.1016/j.jacc.2017.11.047 29389360 · DOI
  115. [122]Cyranoski D ‘Reprogrammed’ stem cells approved to mend human hearts for the first time Nature 2018 557 619 620 10.1038/d41586-018-05278-8 29844563 · DOI
  116. [123]Povsic, T. J. & Gersh, B. J. Stem cells in cardiovascular diseases: 30,000-foot view. Cells10, 600 (2021). PMC8001267 33803227
  117. [124]Romito A Cobellis G Pluripotent stem cells: current understanding and future directions Stem Cells Int. 2016 2016 9451492 10.1155/2016/9451492 26798367 PMC4699068 · DOI
  118. [125]McKenna, S. L. et al. Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. J. Neurosurg. Spine1, 1–10 (2022). 35364569
  119. [126]Deinsberger J Reisinger D Weber B Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis NPJ Regen. Med. 2020 5 15 10.1038/s41536-020-00100-4 32983575 PMC7486930 · DOI · Paper page
  120. [127]Kim JY Nam Y Rim YA Ju JH Review of the current trends in clinical trials involving induced pluripotent stem cells Stem Cell Rev. Rep. 2022 18 142 154 10.1007/s12015-021-10262-3 34532844 PMC8445612 · DOI
  121. [128]Ji P Manupipatpong S Xie N Li Y Induced pluripotent stem cells: generation strategy and epigenetic mystery behind reprogramming Stem Cells Int. 2016 2016 8415010 10.1155/2016/8415010 26880993 PMC4736417 · DOI
  122. [129]Fu X The immunogenicity of cells derived from induced pluripotent stem cells Cell Mol. Immunol. 2014 11 14 16 10.1038/cmi.2013.60 24336164 PMC4002141 · DOI
  123. [130]Lee AS Tang C Rao MS Weissman IL Wu JC Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies Nat. Med. 2013 19 998 1004 10.1038/nm.3267 23921754 PMC3967018 · DOI
  124. [131]Friedenstein AJ Piatetzky S II Petrakova KV Osteogenesis in transplants of bone marrow cells J. Embryol. Exp. Morphol. 1966 16 381 390 5336210
  125. [132]Pittenger MF Multilineage potential of adult human mesenchymal stem cells Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 · DOI · Paper page
  126. [133]Nombela-Arrieta C Ritz J Silberstein LE The elusive nature and function of mesenchymal stem cells Nat. Rev. Mol. Cell Biol. 2011 12 126 131 10.1038/nrm3049 21253000 PMC3346289 · DOI
  127. [135]Zhou T Challenges and advances in clinical applications of mesenchymal stromal cells J. Hematol. Oncol. 2021 14 24 10.1186/s13045-021-01037-x 33579329 PMC7880217 · DOI · Paper page
  128. [136]Ankrum J Karp JM Mesenchymal stem cell therapy: two steps forward, one step back Trends Mol. Med. 2010 16 203 209 10.1016/j.molmed.2010.02.005 20335067 PMC2881950 · DOI
  129. [137]Tuan RS Boland G Tuli R Adult mesenchymal stem cells and cell-based tissue engineering Arthritis Res. Ther. 2003 5 32 45 10.1186/ar614 12716446 PMC154434 · DOI
  130. [138]Witkowska-Zimny M Wrobel E Perinatal sources of mesenchymal stem cells: Wharton’s jelly, amnion and chorion Cell Mol. Biol. Lett. 2011 16 493 514 10.2478/s11658-011-0019-7 21786036 PMC6275796 · DOI
  131. [139]Alkhalil M Smajilagic A Redzic A Human dental pulp mesenchymal stem cells isolation and osteoblast differentiation Med. Glas. (Zenica) 2015 12 27 32 25669333
  132. [140]Ouryazdanpanah N Dabiri S Derakhshani A Vahidi R Farsinejad A Peripheral blood-derived mesenchymal stem cells: growth factor-free isolation, molecular characterization and differentiation Iran. J. Pathol. 2018 13 461 466 30774686 PMC6358558
  133. [141]Francis MP Sachs PC Elmore LW Holt SE Isolating adipose-derived mesenchymal stem cells from lipoaspirate blood and saline fraction Organogenesis 2010 6 11 14 10.4161/org.6.1.10019 20592860 PMC2861738 · DOI
  134. [142]Gong X Isolation and characterization of lung resident mesenchymal stem cells capable of differentiating into alveolar epithelial type II cells Cell Biol. Int. 2014 38 405 411 10.1002/cbin.10240 24403246 · DOI
  135. [143]Wang B Human hair follicle-derived mesenchymal stem cells: Isolation, expansion, and differentiation World J. Stem Cells 2020 12 462 470 10.4252/wjsc.v12.i6.462 32742563 PMC7360986 · DOI
  136. [144]Pilato, C. A. et al. Isolation and characterization of cardiac mesenchymal stromal cells from endomyocardial bioptic samples of arrhythmogenic cardiomyopathy patients. J. Vis. Exp. 132, e57263 (2018). PMC5931414 29553539
  137. [145]Mannino G Adult stem cell niches for tissue homeostasis J. Cell Physiol. 2022 237 239 257 10.1002/jcp.30562 34435361 PMC9291197 · DOI
  138. [146]Pavlushina SV Orlova TG Tabagari DZ [Isolation of mononuclear cells from the bone marrow of patients with hemoblastoses using one-step ficoll-verographin density gradient separation] Eksp. Onkol. 1984 6 68 70 6595113
  139. [147]Schneider S Unger M van Griensven M Balmayor ER Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine Eur. J. Med Res. 2017 22 17 10.1186/s40001-017-0258-9 28526089 PMC5438493 · DOI
  140. [148]Torre, P. & Flores, A. I. Current status and future prospects of perinatal stem cells. Genes12, 6 (2020). PMC7822425 33374593
  141. [149]Hoang, V. T. et al. Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources. Cytotherapy23, 88–99 (2020). 33097415
  142. [150]Mohamed-Ahmed S Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison Stem Cell Res. Ther. 2018 9 168 10.1186/s13287-018-0914-1 29921311 PMC6008936 · DOI · Paper page
  143. [151]Zuk PA Human adipose tissue is a source of multipotent stem cells Mol. Biol. Cell 2002 13 4279 4295 10.1091/mbc.e02-02-0105 12475952 PMC138633 · DOI
  144. [152]Li Z CD133: a stem cell biomarker and beyond Exp. Hematol. Oncol. 2013 2 17 10.1186/2162-3619-2-17 23815814 PMC3701589 · DOI
  145. [153]Petrenko Y A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential Sci. Rep. 2020 10 4290 10.1038/s41598-020-61167-z 32152403 PMC7062771 · DOI
  146. [154]Wang Z Yan X CD146, a multi-functional molecule beyond adhesion Cancer Lett. 2013 330 150 162 10.1016/j.canlet.2012.11.049 23266426 · DOI
  147. [156]Han I Kwon BS Park HK Kim KS Differentiation potential of mesenchymal stem cells is related to their intrinsic mechanical properties Int. Neurourol. J. 2017 21 S24 S31 10.5213/inj.1734856.428 28446012 PMC5426435 · DOI
  148. [157]Song Y Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms World J. Stem Cells 2020 12 1032 1049 10.4252/wjsc.v12.i9.1032 33033563 PMC7524695 · DOI
  149. [158]Lee RH Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 Cell Stem Cell 2009 5 54 63 10.1016/j.stem.2009.05.003 19570514 PMC4154377 · DOI · Paper page
  150. [159]Allers C Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice Transplantation 2004 78 503 508 10.1097/01.TP.0000128334.93343.B3 15446307 · DOI
  151. [160]Devine SM Cobbs C Jennings M Bartholomew A Hoffman R Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates Blood 2003 101 2999 3001 10.1182/blood-2002-06-1830 12480709 · DOI
  152. [161]Fischer UM Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect Stem Cells Dev. 2009 18 683 692 10.1089/scd.2008.0253 19099374 PMC3190292 · DOI · Paper page
  153. [162]Sierra-Parraga JM Mesenchymal stromal cells are retained in the porcine renal cortex independently of their metabolic state after renal intra-arterial infusion Stem Cells Dev. 2019 28 1224 1235 10.1089/scd.2019.0105 31280676 · DOI
  154. [163]Henriksson HB The traceability of mesenchymal stromal cells after injection into degenerated discs in patients with low back pain Stem Cells Dev. 2019 28 1203 1211 10.1089/scd.2019.0074 31237488 · DOI
  155. [164]Sokal EM Biodistribution of liver-derived mesenchymal stem cells after peripheral injection in a hemophilia A patient Transplantation 2017 101 1845 1851 10.1097/TP.0000000000001773 28738402 · DOI
  156. [165]Sood V Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery Clin. Nucl. Med. 2015 40 697 700 10.1097/RLU.0000000000000850 26164170 · DOI
  157. [166]Sanchez-Diaz, M. et al. Biodistribution of mesenchymal stromal cells after administration in animal models and humans: a systematic review. J. Clin. Med.10, 2925 (2021). PMC8268414 34210026
  158. [167]Sensebe L Fleury-Cappellesso S Biodistribution of mesenchymal stem/stromal cells in a preclinical setting Stem Cells Int. 2013 2013 678063 10.1155/2013/678063 24222773 PMC3810433 · DOI
  159. [168]Zhuang WZ Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications J. Biomed. Sci. 2021 28 28 10.1186/s12929-021-00725-7 33849537 PMC8043779 · DOI
  160. [169]Wei X Mesenchymal stem cells: a new trend for cell therapy Acta Pharm. Sin. 2013 34 747 754 10.1038/aps.2013.50 PMC4002895 23736003 · DOI
  161. [170]Kouchakian MR The clinical trials of mesenchymal stromal cells therapy Stem Cells Int. 2021 2021 1634782 10.1155/2021/1634782 34745268 PMC8566082 · DOI
  162. [171]Chen L Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications Cell Mol. Life Sci. 2022 79 142 10.1007/s00018-021-04096-y 35187617 PMC8858603 · DOI
  163. [172]Borow KM Yaroshinsky A Greenberg B Perin EC Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure Circ. Res. 2019 125 265 281 10.1161/CIRCRESAHA.119.314951 31318648 PMC6688717 · DOI
  164. [173]Zheng H Mesenchymal stem cell therapy in stroke: a systematic review of literature in pre-clinical and clinical research Cell Transpl. 2018 27 1723 1730 10.1177/0963689718806846 PMC6300779 30343609 · DOI
  165. [175]Shi L Mesenchymal stem cell therapy for severe COVID-19 Signal Transduct. Target Ther. 2021 6 339 10.1038/s41392-021-00754-6 34497264 PMC8424619 · DOI
  166. [176]Carney BJ Shah K Migration and fate of therapeutic stem cells in different brain disease models Neuroscience 2011 197 37 47 10.1016/j.neuroscience.2011.08.063 21946010 PMC3589128 · DOI
  167. [177]Yao P Zhou L Zhu L Zhou B Yu Q Mesenchymal stem cells: a potential therapeutic strategy for neurodegenerative diseases Eur. Neurol. 2020 83 235 241 10.1159/000509268 32690856 · DOI
  168. [178]Bonaventura, G. et al. Stem cells: innovative therapeutic options for neurodegenerative diseases? Cells10, 1992 (2021). PMC8391848 34440761
  169. [179]Mansoor SR Zabihi E Ghasemi-Kasman M The potential use of mesenchymal stem cells for the treatment of multiple sclerosis Life Sci. 2019 235 116830 10.1016/j.lfs.2019.116830 31487529 · DOI
  170. [180]Chung JW Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke Neurology 2021 96 e1012 e1023 10.1212/WNL.0000000000011440 33472925 · DOI
  171. [181]Yamazaki, K., Kawabori, M., Seki, T. & Houkin, K. Clinical trials of stem cell treatment for spinal cord injury. Int. J. Mol. Sci. 21, 3994 (2020). PMC7313002 32498423
  172. [182]Xie B Chen M Hu R Han W Ding S Therapeutic evidence of human mesenchymal stem cell transplantation for cerebral palsy: a meta-analysis of randomized controlled trials Stem Cells Int. 2020 2020 5701920 10.1155/2020/5701920 32765613 PMC7387980 · DOI
  173. [183]McDonald, C. A. et al. Intranasal delivery of mesenchymal stromal cells protects against neonatal hypoxic(-)ischemic brain injury. Int. J. Mol. Sci. 20, 2449 (2019). PMC6566762 31108944
  174. [184]Liu Q Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders World J. Stem Cells 2019 11 55 72 10.4252/wjsc.v11.i2.55 30842805 PMC6397804 · DOI
  175. [185]Fricova D Korchak JA Zubair AC Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease npj Regen. Med. 2020 5 20 10.1038/s41536-020-00106-y 33298940 PMC7641157 · DOI
  176. [186]Bang OY Lee JS Lee PH Lee G Autologous mesenchymal stem cell transplantation in stroke patients Ann. Neurol. 2005 57 874 882 10.1002/ana.20501 15929052 · DOI
  177. [187]Lee JS A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke Stem Cells 2010 28 1099 1106 10.1002/stem.430 20506226 · DOI
  178. [188]Honmou O Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke Brain 2011 134 1790 1807 10.1093/brain/awr063 21493695 PMC3102237 · DOI
  179. [189]Bhasin A Autologous mesenchymal stem cells in chronic stroke Cerebrovasc. Dis. Extra 2011 1 93 104 10.1159/000333381 22566987 PMC3343764 · DOI
  180. [190]Jaillard A Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial Transl. Stroke Res. 2020 11 910 923 10.1007/s12975-020-00787-z 32462427 · DOI
  181. [191]Lee J Efficacy of intravenous mesenchymal stem cells for motor recovery after ischemic stroke: a neuroimaging study Stroke 2022 53 20 28 10.1161/STROKEAHA.121.034505 34583525 · DOI
  182. [192]Levy ML Phase I/II study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke Stroke 2019 50 2835 2841 10.1161/STROKEAHA.119.026318 31495331 · DOI
  183. [193]Xu P Yang X The efficacy and safety of mesenchymal stem cell transplantation for spinal cord injury patients: a meta-analysis and systematic review Cell Transpl. 2019 28 36 46 10.1177/0963689718808471 PMC6322141 30362373 · DOI
  184. [194]Liau LL Treatment of spinal cord injury with mesenchymal stem cells Cell Biosci. 2020 10 112 10.1186/s13578-020-00475-3 32983406 PMC7510077 · DOI
  185. [195]Liu, X. et al. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J. Transl. Med.15, 1–9 (2017). PMC5324263 28235424
  186. [196]Sharma, A. K. et al. Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study. Am J. Stem Cells9, 89 (2020). PMC7811933 33489466
  187. [197]Ballen K Kurtzberg J Exploring new therapies for children with autism: “Do no harm” does not mean do not try Stem Cells Transl. Med. 2021 10 823 825 10.1002/sctm.20-0548 34010518 PMC8133345 · DOI
  188. [198]Reyhani S Abbaspanah B Mousavi SH Umbilical cord-derived mesenchymal stem cells in neurodegenerative disorders: from literature to clinical practice Regen. Med. 2020 15 1561 1578 10.2217/rme-2019-0119 32479211 · DOI
  189. [199]Gu J Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial Stem Cell Res Ther. 2020 11 43 10.1186/s13287-019-1545-x 32014055 PMC6998370 · DOI
  190. [200]Retraction. Stem Cells Transl. Med.10, 1717 (2021). PMC8641073 34847283
  191. [201]Sun JM Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder Stem Cells Transl. Med. 2020 9 1137 1146 10.1002/sctm.19-0434 32531111 PMC7519773 · DOI
  192. [202]Yang, Y. et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy23, 57–64 (2021). 33218835
  193. [203]Liu J Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells Cytotherapy 2013 15 185 191 10.1016/j.jcyt.2012.09.005 23321330 · DOI
  194. [204]Przekora A Juszkiewicz L The effect of autologous adipose tissue-derived mesenchymal stem cells’ therapy in the treatment of chronic posttraumatic spinal cord injury in a domestic ferret patient Cell Transpl. 2020 29 963689720928982 10.1177/0963689720928982 PMC7563821 32441545 · DOI
  195. [205]Hur JW Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial J. Spinal Cord. Med. 2016 39 655 664 10.1179/2045772315Y.0000000048 26208177 PMC5137573 · DOI
  196. [206]de Celis-Ruiz E Final results of allogeneic adipose tissue-derived mesenchymal stem cells in acute ischemic stroke (AMASCIS): a phase II, randomized, double-blind, placebo-controlled, single-center, pilot clinical trial Cell Transpl. 2022 31 9636897221083863 PMC8943307 35301883
  197. [207]Yang Y Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial Neural Regen. Res. 2020 15 1532 1538 10.4103/1673-5374.274347 31997819 PMC7059580 · DOI
  198. [208]de Celis-Ruiz E Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol BMJ Open 2021 11 e051790 10.1136/bmjopen-2021-051790 34373315 PMC8354278 · DOI
  199. [209]Murray CJL COVID-19 will continue but the end of the pandemic is near Lancet 2022 399 417 419 10.1016/S0140-6736(22)00100-3 35065006 PMC8769657 · DOI
  200. [210]Thebaud B Bronchopulmonary dysplasia Nat. Rev. Dis. Prim. 2019 5 78 10.1038/s41572-019-0127-7 31727986 PMC6986462 · DOI

200 of 481 shown

Cited by

Sorted by citations

Authors
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., Heke, M., & Nguyen, L. T.
Affiliations
  • Vinmec Research Institute of Stem Cell and Gene Technology (VN)
  • Vinmec Healthcare System (VN)
  • Keele University (GB)
  • Stanford University (US)
Corresponding author
Hoang, Duc M.
ORCID
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2022-08-06
Volume
7
Issue
1
Pages
272-272
ISSN
2059-3635 (ISSN-L)
DOI
10.1038/s41392-022-01134-4
PMC
PMC9357075
OpenAlex
W4289979044
Cited by
1,074
References
19
Citations by year
2026: 153 · 2025: 370 · 2024: 370 · 2023: 161 · 2022: 19 · 2021: 1
FWCI
38.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Keele Research Repository (Keele University) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Vingroup Scientific Research and Clinical Application Fund
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
stem cell therapy, human pluripotent stem cells, mesenchymal stem cells, regenerative medicine, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, umbilical cord-derived stem cells, neurological disorders, lung disease, acute respiratory distress syndrome, reproductive disorders, skin regeneration, burns, cardiovascular disease, endocrine and metabolic diseases, clinical trials
MeSH terms
Adipose Tissue, Cell Differentiation, Humans, Umbilical Cord, Regenerative Medicine, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review